Young doctor working

2014 Financial results

First quarter results 2014

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

“The first quarter has seen continued momentum across the business and our revenue growth reflects the increasing contribution from the five growth platforms that showed strong performance.

“I am pleased with the significant progress we are making towards achieving scientific leadership in our core therapeutic areas. We have confirmed our decision to advance four programmes to Phase III in oncology and respiratory disease. The Breakthrough Therapy designation for AZD9291 in non-small cell lung cancer and the Priority Review granted for olaparib in ovarian cancer by the FDA act as a reminder of the distinctive science that AstraZeneca can bring to patients.

“We are investing in our rapidly progressing pipeline and the key platforms that are the backbone of our strategy to return to growth. To further concentrate organisational focus, we will continue to redeploy our resources in our core priorities and pursue opportunities that maximise the value of our pipeline and portfolio.”

Teleconference replay

A recording of the analyst presentation and Q&A session will be available until 13:30BST Wednesday 7 May on the following numbers:

LocationNumberConference ID
UK local 0800 953 1533 29609452#
US (freephone) 1 866 247 4222 29609452#
International +44 (0) 1452 55 00 00 29609452#


Keeping investors in touch

Download our iPad app now from the app store

The AstraZeneca Investor Relations iPad app provides instant access to our latest news, webcasts and presentations, events and leadership videos.

Download and install from the iTunes store